Tag Archives: Astellas

ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer

Pfizer and Astellas’ Xtandi is already approved to treat non-metastatic castration-resistant prostate cancer, thanks to data showing it can stop tumors from spreading. But now it’s adding results that show it can help patients live longer, too. When paired with androgen deprivation therapy (ADT), Xtandi cut patients’ risk of death by 27%, a study abstract… Read More »